Supprelin-LA FDA Approval History
FDA Approved: Yes (First approved May 3, 2007)
Brand name: Supprelin-LA
Generic name: histrelin acetate
Dosage form: Subcutaneous Implant
Company: Indevus Pharmaceuticals, Inc.
Treatment for: Precocious Puberty
Supprelin-LA is a once-yearly implant of the gonadotropin releasing hormone (GnRH) analog histrelin, indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children.
Development timeline for Supprelin-LA
| Date | Article |
|---|---|
| May 4, 2007 | Approval Indevus Announces FDA Approval of Supprelin-LA |
| Sep 7, 2006 | Valera Pharmaceuticals Receives PDUFA Date for Supprelin-LA |
| Jul 6, 2006 | Valera Pharmaceuticals Submits NDA for Supprelin-LA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
